Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)
Status:
Active, not recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, open-label, randomized, comparator-controlled study to
evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult
patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b
will be administered on day 1. After safety evaluation of first dose, next dose (second dose)
1 mcg/kg on day 8 will be administered with recommended standard care during the trial.